We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





COVID-19 Molecular Gene Test Uses Nanosensor Technology to Detect Early and Asymptomatic Infections

By LabMedica International staff writers
Posted on 01 Feb 2022

A molecular gene test based on innovative nanosensor technology could reshape the future of COVID-19 diagnostic testing. More...

IdentifySensors Biologics (Shaker Heights, OH, USA), along with researchers at Purdue University (West Lafayette, IN, USA), has developed the new digital technology that aims to replace 50-year PCR testing for multiple infections, including COVID variants. It has finalized proof-of-concept research for its all-new COVID-19 testing method. IdentifySensors is currently in the commercialization stage with Check4, its testing platform that comprises two parts - a re-useable reader and cartridges that intend to check for several infections and pathogens. The first cartridges are intended to test for COVID and the multiple variants, and then a multiplex cartridge which will test for COVID and influenza A and B.

Check4 intends to be a highly accurate, over-the-counter self-test that is fast, accurate, and affordable. It detects early and asymptomatic infections with the accuracy of a PCR test, but without all the necessary reagents, machines, people, and delays. It is intended to avoid the limitations of current molecular tests such as enzymatic reactions, amplification, sample preservation or sample transportation, which can introduce artifacts and raise the risk of false positives. It is not an inaccurate antigen test. This electronic-based disruptive technology intends to use newly-developed nanosensors, saliva, and a user’s smartphone to disrupt the way testing is done now, and into the future. Using saliva and the user’s smartphone, results will be delivered within minutes. Check4 is easy to use and fast, accurate, and affordable. Future intended tests include MRSA, Lyme, Hep C and B, foodborne pathogens, and more.

“With COVID still raging around the globe, our test is a game-changer,” said Dr. Gregory Hummer, founder of IdentifySensors Biologics. “It’s fast, affordable and intends to provide accurate results withing minutes on your smartphone. Check4 can help us get back to living a more normal life.”

Related Links:
IdentifySensors Biologics 
Purdue University


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Collection and Transport System
PurSafe Plus®
Clinical Chemistry System
P780
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.